

CLAIMS

1. A composition for treating autism, comprising:  
genomeceutical material of the type that affects  
expression of a DPPIV like compounds when ingested by a  
5 human in such a manner as to relieve symptoms of autism;  
and  
one or more of a protease, peptidase or phytase.
2. The composition of claim 1, wherein said  
10 genomeceutical material includes galactose.
3. The composition of claim 1, wherein said  
genomeceutical material includes glucans.
- 15 4. The composition of claim 1, wherein said  
genomeceutical material includes a milk sugar other than  
galactose.
5. The composition of claim 1, wherein said DPPIV  
20 like compound includes DPPIV or QPP.
6. The composition of claim 1, wherein said  
protease includes at least one of an acid fast protease  
and a cystein protease.  
25
7. The composition of claim 6, wherein said cystein  
protease is bromelain or papain.
8. The composition of claim 1, comprising both a  
30 protease and a phytase.
9. The composition of claims 1, further including  
phospholipid promoting compound.

10. The composition of claims 1, further including a disaccharidase compound.

5        11. The composition of claims 1, further including a lipase compound.

12. A composition for treating autism, comprising:  
a phytase like compound; and  
10        one or more of a genomeceutical for treating autism  
or a protease for treating autism.

09072515-060101  
101090-51922860